Key result
Rifampicin co-administration requires a ~200% higher warfarin dose to maintain therapeutic INR.
Why the study?
Rifampicin substantially reduces warfarin efficacy via cytochrome P450 induction, requiring structured monitoring and individualized dose adjustment to maintain therapeutic anticoagulation.
Population
1 64-year-old Chinese male with chronic thromboembolic pulmonary hypertension receiving warfarin and rifampicin-containing antituberculosis treatment
Design
Case report
Authors
Loading...
Rifampicin may triple warfarin requirements in select patients; this case report supports the interaction but leaves open prospective dose-adjustment protocols.
Case Report (n=1)
No
Rifampicin co-administration can increase warfarin requirements by approximately 200%, necessitating frequent INR monitoring and individualized dose adjustments to maintain safe anticoagulation.
Li et al. (2026) conducted a case report in Chronic thromboembolic pulmonary hypertension (n=1). Rifampicin co-administration during warfarin therapy was evaluated on Warfarin dose requirement and therapeutic INR achievement. Rifampicin co-administration increased the patient's warfarin requirement from 1.5 mg/day to 4.5 mg/day to maintain a therapeutic INR without bleeding or thromboembolic events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: